noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the Oppenheimer & Co., Inc. 26th Annual Healthcare Conference in New York City on December 8, 2015 at 9:45 a.m. EST.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in Boston and New York, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com.
KERYX CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
